Close

Tobira Therapeutics (TBRA) Completes Recruitment for ORION Phase 2a Study in NAFLD

February 9, 2016 8:44 AM EST Send to a Friend
Tobira Therapeutics, Inc. (NASDAQ: TBRA), a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis (NASH) and other serious immuno-inflammatory ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login